fosaprepitant

Ivemend · ATC code A04AD12

Brand names: Ivemend, Fosaprepitant Accord, Fosaprepitant Hikma, Fosaprepitant Amarox, Fosaprepitant-Dimeglumin Tillomed, Fosaprepitant Stada, Emend, Fosaprant, Fosemazon, Fosemitant

Key facts
Active substance: fosaprepitant
ATC code: A04AD12
Authorisation: centrally authorised across the EU (EMA)
Dosage forms: IVEMEND 150 mg powder for solution for infusion.
Marketing authorisation holder: Merck Sharp & Dohme B.V.
Information as of: 2026-10-28

Key facts

Fosaprepitant (Ivemend) is an intravenous prodrug of aprepitant, an NK1 receptor antagonist. It is used to prevent nausea and vomiting with chemotherapy.

What it is used for

Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and children aged 6 months and older, as part of combination therapy.

Dosing

Adults: 150 mg infused over 20-30 minutes on Day 1, starting approximately 30 minutes before chemotherapy, with a corticosteroid and a 5-HT3 antagonist.
Highly emetogenic chemotherapy (adults): dexamethasone 12 mg on Day 1, 8 mg on the second day and 8 mg twice daily on the third and fourth days.
Moderately emetogenic chemotherapy (adults): dexamethasone 12 mg on Day 1 only.
Children aged 6 months and older (at least 6 kg): age-based regimens, e.g. 12 years and older 115 mg on Day 1, then 80 mg; see the full text.

Contraindications

Hypersensitivity to the active substance, polysorbate 80 or any of the other excipients.
Co-administration with pimozide, terfenadine, astemizole or cisapride.

Important warnings

Immediate hypersensitivity reactions including anaphylaxis during or soon after infusion; do not reinitiate the infusion.
Infusion site reactions have been reported.
Use with caution in moderate to severe hepatic impairment.
Caution with CYP3A4 substrates with a narrow therapeutic range (e.g. ciclosporin, tacrolimus, fentanyl) and with irinotecan.
In patients on warfarin, monitor INR closely for 14 days.

Side effects

More frequent than with standard therapy (aprepitant, adults): hiccups, ALT increased, dyspepsia, constipation, headache, decreased appetite; fatigue with MEC.
In children: hiccups and flushing.

Interactions

Weak CYP3A4 inhibitor; may increase levels of CYP3A4 substrates.
Hormonal contraceptive efficacy may be reduced during and for 28 days after administration; use non-hormonal back-up contraception for 2 months.
The dexamethasone doses in the regimen already account for the interaction.

Pregnancy and breastfeeding

No clinical data on exposed pregnancies; reproductive toxicity potential not fully characterised. See the full text.

Summary of the official product information, written with AI on 2026-10-29. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

This product has no separate US patient information.

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

IvemendMerck Sharp & Dohme B.V. · EMEA/H/C/000743

Source: European Medicines Agency (EMA), product information

Austria

Fosaprepitant AccordAccord Healthcare B.V. · 1 register entry
Fosaprepitant HikmaHikma Farmacêutica (Portugal), S.A. · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Germany

Fosaprepitant AmaroxAmarox Pharma Gmbh · 1 register entry
Fosaprepitant-Dimeglumin TillomedTillomed Pharma Gmbh · 1 register entry
Fosaprepitant HikmaHikma Farmacêutica (Portugal), S.A. · 1 register entry
Fosaprepitant StadaStadapharm Gmbh · 1 register entry

Source: EMA – Article 57 product data (EU/EEA), as of 2026-10-29

Turkey

EmendMERCK SHARP DOHME İLAÇLARI LTD. ŞTİ. · 1 register entry
FosaprantVEM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
FosemazonPOLİFARMA İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
FosemitantAROMA İLAÇ SAN. LTD. ŞTİ. · 1 register entry

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 9 more European countries

Finland: Fosaprepitant Accord
Iceland: Ivemend
Italy: Fosaprepitant Accord, Fosaprepitant Hikma
Liechtenstein: Ivemend
Netherlands: Fosaprepitant Amarox
Norway: Fosaprepitant Accord, Ivemend
Portugal: Fosaprepitant Accord, Fosaprepitant Farmoz, Fosaprepitant Hikma, Fosaprepitant Tecnigen
Spain: Fosaprepitant Accord, Fosaprepitant Hikma, Fosaprepitant Tarbis, Fosaprepitant Tecnigen
Sweden: Fosaprepitant Accord

EMA – Article 57 product data (EU/EEA), 2026-10-29

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Other substances in the same group

aprepitant

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

European Medicines Agency. Ivemend – EPAR, Product Information. 2026-10-28. https://www.ema.europa.eu/en/documents/product-information/ivemend-epar-product-information_en.pdf
EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
EMA – Article 57 product data (EU/EEA), 2026-10-29. https://www.ema.europa.eu/en/human-regulatory-overview/post-authorisation/data-medicines-iso-idmp-standards-post-authorisation/public-data-article-57-database
TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-28 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.